Rubius Therapeutics Inc (NASDAQ:RUBY) – Equities researchers at Jefferies Financial Group lowered their FY2018 earnings estimates for shares of Rubius Therapeutics in a report issued on Tuesday, November 13th, according to Zacks Investment Research. Jefferies Financial Group analyst M. Yee now anticipates that the company will post earnings per share of ($2.80) for the year, down from their previous estimate of ($2.61). Jefferies Financial Group has a “Buy” rating and a $40.00 price target on the stock. Jefferies Financial Group also issued estimates for Rubius Therapeutics’ Q4 2018 earnings at ($0.46) EPS, FY2019 earnings at ($2.20) EPS and FY2020 earnings at ($2.77) EPS.

A number of other research firms have also recently commented on RUBY. Morgan Stanley began coverage on Rubius Therapeutics in a research report on Monday, August 13th. They set an “overweight” rating and a $37.00 target price on the stock. Zacks Investment Research cut Rubius Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 15th. JPMorgan Chase & Co. began coverage on Rubius Therapeutics in a research report on Monday, August 13th. They set an “overweight” rating on the stock. Finally, Leerink Swann began coverage on Rubius Therapeutics in a research report on Monday, August 13th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Rubius Therapeutics currently has an average rating of “Buy” and a consensus target price of $38.50.

NASDAQ RUBY traded down $1.93 during trading on Friday, reaching $19.30. 274,684 shares of the company’s stock were exchanged, compared to its average volume of 99,364. The company has a quick ratio of 25.78, a current ratio of 25.78 and a debt-to-equity ratio of 0.06. Rubius Therapeutics has a 1 year low of $14.50 and a 1 year high of $33.01.

Rubius Therapeutics (NASDAQ:RUBY) last announced its quarterly earnings results on Tuesday, November 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.06).

Institutional investors and hedge funds have recently bought and sold shares of the company. American International Group Inc. acquired a new stake in shares of Rubius Therapeutics during the third quarter worth about $194,000. Rhumbline Advisers acquired a new stake in shares of Rubius Therapeutics during the third quarter worth about $207,000. Zimmer Partners LP acquired a new stake in shares of Rubius Therapeutics during the third quarter worth about $360,000. TIAA CREF Investment Management LLC acquired a new position in Rubius Therapeutics in the 3rd quarter valued at about $392,000. Finally, MetLife Investment Advisors LLC acquired a new position in Rubius Therapeutics in the 3rd quarter valued at about $405,000. Institutional investors and hedge funds own 81.17% of the company’s stock.

About Rubius Therapeutics

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.

Read More: Catch-Up Contributions

Get a free copy of the Zacks research report on Rubius Therapeutics (RUBY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Rubius Therapeutics (NASDAQ:RUBY)

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.